https://www.selleckchem.com/pr....oducts/eidd-2801.htm
Results AKI developed in 10 of 32 patients (31.25%) who were using vancomycin + piperacillin-tazobactam. On the other hand, 13 of 32 patients (40.62%) were using cefotaxime + vancomycin (p = 0.047). Of the 10 patients who were on vancomycin + piperacillin-tazobactam regimen, 80% developed AKI Stage I. Of the 13 patients who were using cefotaxime + vancomycin, 46% developed AKI Stage II, although no statistical significance was noted in all stages. Conclusion Our study showed that patients treated with cefotaxime and vancomycin showed
Mi piace
Commento
Condividi
